



Contact: Aaron Berstler or Laura Aumann, Kohnstamm Communications (651) 228-9141

FACT SHEET

ProUroScan

About ProUroScan

ProUroScan™ is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a clear full-color digital image. The system utilizes “elasticity imaging technology” to measure and digitize organ tissue density and displacement and generate a composite metric “map” that visualizes and documents abnormalities of the prostate detected by digital rectal exam (DRE). A 510(k) will be filed with the FDA for this technology in 2009.

Elasticity Imaging

Elasticity imaging refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Sensors on the head of the probe collect a sequence of pressure patterns while the probe is pressed against the prostate. The device consequently measures the prostate’s elasticity and assigns an “elasticity contrast number.” Each scan produces an image of the prostate and compares elasticity measurements across the gland.

Tissue Displacement

Tissue displacement occurs anytime body tissue moves in response to pressure. As areas of abnormal tissue form within an organ, the tissue often becomes more dense and less elastic. When pressure is applied to the organ, abnormal tissue exhibits less displacement than normal tissue. This difference can be detected and measured.

A Prostate Map

The image or “map” of the prostate that is created is designed to identify variations in tissue elasticity using a highly sensitive rectal probe. Abnormal prostate tissue exhibits less elastic properties and is represented by progressively darker areas on the image of the map as compared to normal tissue. During the real-time imaging examination, the physician can direct the probe to specific areas of interest as confirmed by DRE. The final or “composite” image is saved in a file as a permanent electronic record.

Commercialization Process

ProUroScan is an innovative product for which FDA clearance will be sought for use as an aid to the physician in visualizing and documenting abnormalities of the prostate detected by DRE. A product of medical diagnostic product maker ProUroCare Medical Inc. (OTCBB: PUMD) developed in collaboration with ARTANN Laboratories, the imaging system recently completed its clinical trials and a 510(k) application for clearance for marketing in the United States is expected to be filed soon.

ABOUT PROUROCARE MEDICAL INC: ProUroCare Medical Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company’s current focus is the ProUroScan prostate imaging system, which recently completed clinical trials for the mapping of prostate abnormalities detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB market.

###